CELL AND GENE THERAPY

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

August 24, 2022

Use of PS-DVB
The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

Spotlight

LC Sciences

LC Sciences is a global biotechnology company providing products and services to genomics and proteomics researchers across an array of markets for nucleic acid/protein analysis, biomarker-discovery and drug development. Our innovative products and comprehensive services are based on several unique, core technology platforms developed by the scientists here at LC Sciences. A wide range of microarray service products are based on our µParaflo® microfluidic on-chip synthesis technology. This technology enables us to provide unique and customizable arrays of oligonucleotides, peptides, and their analog molecules. Our line of microarray services includes microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays.

OTHER WHITEPAPERS
news image

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Read More
news image

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Read More
news image

Multi-Attribute Methods for Biopharmaceutical Analysis

whitePaper | December 5, 2022

The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.

Read More
news image

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Read More
news image

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Read More
news image

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Read More

Spotlight

LC Sciences

LC Sciences is a global biotechnology company providing products and services to genomics and proteomics researchers across an array of markets for nucleic acid/protein analysis, biomarker-discovery and drug development. Our innovative products and comprehensive services are based on several unique, core technology platforms developed by the scientists here at LC Sciences. A wide range of microarray service products are based on our µParaflo® microfluidic on-chip synthesis technology. This technology enables us to provide unique and customizable arrays of oligonucleotides, peptides, and their analog molecules. Our line of microarray services includes microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays.

Events